Anadys to raise $12.5 million but weighs up options
This article was originally published in Scrip
Executive Summary
Anadys Pharmaceuticals' future remains uncertain after it announced plans to raise $12.5 million through a stock-sale but retained Lazard Frères as its strategic advisor to pursue options for its lead compound ANA598.